84332-02-5

Basic information

• Product Name: 3-Pyridinecarboxylic acid, 6-chloro-4-methoxy-, methyl ester
• Synonyms: 3-Pyridinecarboxylic acid, 6-chloro-4-methoxy-, methyl ester;6-Chloro-4-Methoxynicotinic acid Methyl ester;Methyl 6-chloro-4-methoxypyridine-3-carboxylate;Methyl 6-chloro-4-Methoxynicotinate
• CAS NO: 84332-02-5
• Molecular Formula: C₈H₈ClNO₃
• Molecular Weight: 202
• Mol File: 84332-02-5.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 283.6±35.0℃ (760 Torr)
• Flash Point: 125.3±25.9℃
• Appearance: /
• Density: 1.288±0.06 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 0.04±0.10(Predicted)
• CAS DataBase Reference: 3-Pyridinecarboxylic acid, 6-chloro-4-methoxy-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridinecarboxylic acid, 6-chloro-4-methoxy-, methyl ester(84332-02-5)
• EPA Substance Registry System: 3-Pyridinecarboxylic acid, 6-chloro-4-methoxy-, methyl ester(84332-02-5)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 84332-02-5(Hazardous Substances Data)

Usage

General Description

3-Pyridinecarboxylic acid, 6-chloro-4-methoxy, methyl ester is a chemical compound that is the methyl ester of 6-chloro-4-methoxypyridine-3-carboxylic acid. It is a derivative of pyridinecarboxylic acid, possessing a chlorine atom at the 6 position and a methoxy group at the 4 position. 3-Pyridinecarboxylic acid, 6-chloro-4-methoxy-, methyl ester is commonly used in organic synthesis and medicinal chemistry research as a building block for the synthesis of various pharmaceutical compounds. It may also have potential applications in the development of new drugs and agrochemicals due to its unique structure and reactivity.

Upstream product

• 65973-52-6 methyl 4,6-dichloropyridine-3-carboxylate 
• 124-41-4 sodium methylate 
• 162371-83-7 6-chloro-4-hydroxy-nicotinic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 1830-54-2 3-oxopentanedioic acid dimethyl ester 
• 79398-27-9 methyl 4,6-dihydroxypyridine-3-carboxylate 
• 67-56-1 methanol 

Downstream Products

• 84332-04-7 2-(2-amino-4-methoxy-5-pyridyl-carboxamidomethyl)-1-ethylpyrrolidine 
• 1173177-02-0 1-((R)-4-benzoyl-2-methylpiperazin-1-yl)-2-[6-chloro-4-methoxypyridin-3-yl]ethane-1,2-dione 
• 1246765-64-9 (R)-6-(1-(3-chloro-4-cyanophenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-4-methoxynicotinic acid 
• 716362-10-6 6-chloro-4-methoxypyridine-3-carboxylic acid 
• 1256819-61-0 methyl 6-bromo-4-methoxy pyridine-3-carboxylate 
• 1256823-05-8 6-chloro-4-methoxypyridine-3-carbaldehyde 
• 1263059-66-0 (6-chloro-4-methoxypyridin-3-yl)methanol 

Relevant articles and documents

1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS

Compounds according to formula I or II are useful as agonists of Toll-like receptor 7 (TLR7). (I) (II) Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.

TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF

The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKKε inhibitors.

5-(PYRIDIN-2-YL-AMINO)-PYRAZINE-2-CARBONITRILE COMPOUNDS AND THEIR THERAPEUTIC USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain pyridyl-amino-pyrazine carbonitrile compounds that, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) aDNA damaging agent; (c) an antimetabolite or thymidylate synthase (TS) inhibitor; (d) a microtubule targeted agent; and (e) ionisin g radiation.